The Alopecia Treatment Market has been divided into alopecia totalis, traction alopecia, cicatricial alopecia, and other types of alopecia. Due to the increasing number of regulatory approvals resulting in an increase in the number of medications treating alopecia, the alopecia areata category is anticipated to account for the biggest revenue share throughout the projected period. For instance, on June 13, 2022, the Food and Drug Administration (FDA) of the United States approved Olumiant (baricitinib) oral tablets for the treatment of adult patients with severe alopecia areata, a condition that results in patchy baldness and affects over 300,000 people in the country each year. This procedure marks the FDA's first approval of a systemic treatment for alopecia areata (one that addresses the entire body rather than a specific spot).
During the projection period, the CAGR for the AGA segment is anticipated to be high. Alopecia Treatment Market expansion is being fueled by growing public awareness of this ailment, which is being driven by proactive initiatives by many organisations and the availability of laser-based AGA treatment options. To give one example, effective initiatives by groups like the Alopecia World, American Hair Loss Association, and Hairmax (Lexington International), who also created National Hair Loss Awareness Month, are helping to increase public awareness of these disorders. Significant increase is being seen in the number of companies offering painless therapeutic alternatives for treating AGA, including Hairmax, Lexington International, iRestore Hair Growth System (Freedom Laser Therapeutic), and LUTRONIC.
Source Link- https://cmi-latestreportorientedblogs.blogspot.com/2023/02/alopecia-treatment-market-size-share.html
